Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
2023 · Nature Communications · 31 citations
https://doi.org/10.1038/s41467-023-42400-5
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
7
Papers
64
Citations
3
h-index
3
i10-index
Timothy Wohlfromm is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Cancer Diagnosis and Treatment & DNA Repair Mechanisms & Epigenetics and DNA Methylation. The author has an h-index of 3, co-authored 6 publications.
Click to start Chat